Product Code: GVR-4-68040-138-6
Leadless Pacemakers Market Growth & Trends:
The global leadless pacemakers market size is expected to reach USD 1.74 billion by 2030, growing at a CAGR of 15.5% from 2024 to 2030, based on a new report by Grand View Research, Inc. This growth is attributed to technological advancements, rising prevalence of heart diseases, and a preference for minimally invasive procedures. Moreover, the growing aging population globally propels the demand for leadless pacemakers, as bradycardia is common in the geriatric population. According to the Cleveland Clinic, approximately half a million of the geriatric population show the symptoms of bradycardia, thereby driving the industry.
Wireless or leadless pacemakers, frequently used in adult patients, have emerged as a potentially safe and efficient temporary alternative for children experiencing bradycardia, as revealed by research featured in Circulation: Arrhythmia and Electrophysiology, a peer-reviewed journal affiliated with the American Heart Association. This development is expected to be a potential driver for the market growth.
In addition, growing business initiatives by companies for leadless pacemakers propel the industry's growth. For instance, in January 2024, Medtronic plc announced it had received the CE (Conformite Europeenne) Mark for its Micra AV2 and Micra VR2, leadless pacemakers.The Micra AV2 and Micra VR2, which are recognized as the smallest pacemakers globally, offer extended battery life and simplified programming in comparison to earlier models of Micra pacemakers. Despite these advancements, they retain the numerous advantages of leadless pacing, including a reduction in complications when compared to traditional pacemakers.
Leadless Pacemakers Market Report Highlights:
- Based on the pacing chamber, single chamber accounted for the largest revenue market share of 54.84% in 2023 due to the suitability for a broader range of patients with bradycardia or heart block
- Based on the pacing chamber, the dual chamber segment is expected to grow at the fastest CAGR of 16.3% during the forecast period owing to their ability to address a broader range of cardiac conditions
- Based on the end-use, the hospital segment accounted for the largest market share of 88.86% in 2023 due to their functioning as crucial centers for patient recruitment and engagement in these trials
- In 2023, North America dominated with a share of 54.92% due to technological advancements, increasing heart diseases, and accessibility and availability of skilled professionals. Asia Pacific is expected to grow at the fastest CAGR of 16.9% during the forecast period the growing collaborations, increasing health expenditure, government initiatives, increasing CVD, and geographic expansion
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Pacing Chamber
- 1.2.2. End-use
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Pacing Chamber Outlook
- 2.2.2. End-use Outlook
- 2.2.3. Region Outlook
- 2.3. Competitive Insights
Chapter 3. Leadless Pacemakers Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Leadless Pacemakers Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Leadless Pacemakers Market: Pacing Chamber Estimates & Trend Analysis
- 4.1. Pacing Chamber Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Leadless Pacemakers Market by Pacing Chamber Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
- 4.5. Single Chamber'
- 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.6. Dual Chamber
- 4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Leadless Pacemakers Market: End-use Estimates & Trend Analysis
- 5.1. End-use Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Leadless Pacemakers Market by End-use Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
- 5.5. Hospitals
- 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6. Outpatient Facilities
- 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Leadless Pacemakers Market: Regional Estimates & Trend Analysis by Pacing Chamber & End-use
- 6.1. Regional Dashboard
- 6.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.3. North America
- 6.3.1. North America Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Key Country Dynamics
- 6.3.2.2. Competitive Scenario
- 6.3.2.3. Regulatory Framework
- 6.3.2.4. Reimbursement scenario
- 6.3.2.5. U.S. Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Canada
- 6.3.3.1. Key Country Dynamics
- 6.3.3.2. Competitive Scenario
- 6.3.3.3. Regulatory Framework
- 6.3.3.4. Reimbursement scenario
- 6.3.3.5. Canada Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Europe
- 6.4.1. Europe Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. UK
- 6.4.2.1. Key Country Dynamics
- 6.4.2.2. Competitive Scenario
- 6.4.2.3. Regulatory Framework
- 6.4.2.4. Reimbursement scenario
- 6.4.2.5. UK Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Germany
- 6.4.3.1. Key Country Dynamics
- 6.4.3.2. Competitive Scenario
- 6.4.3.3. Regulatory Framework
- 6.4.3.4. Reimbursement scenario
- 6.4.3.5. Germany Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.4. France
- 6.4.4.1. Key Country Dynamics
- 6.4.4.2. Competitive Scenario
- 6.4.4.3. Regulatory Framework
- 6.4.4.4. Reimbursement scenario
- 6.4.4.5. France Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.5. Italy
- 6.4.5.1. Key Country Dynamics
- 6.4.5.2. Competitive Scenario
- 6.4.5.3. Regulatory Framework
- 6.4.5.4. Reimbursement scenario
- 6.4.5.5. Italy Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.6. Spain
- 6.4.6.1. Key Country Dynamics
- 6.4.6.2. Competitive Scenario
- 6.4.6.3. Regulatory Framework
- 6.4.6.4. Reimbursement scenario
- 6.4.6.5. Spain Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.7. Denmark
- 6.4.7.1. Key Country Dynamics
- 6.4.7.2. Competitive Scenario
- 6.4.7.3. Regulatory Framework
- 6.4.7.4. Reimbursement scenario
- 6.4.7.5. Denmark Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.8. Norway
- 6.4.8.1. Key Country Dynamics
- 6.4.8.2. Competitive Scenario
- 6.4.8.3. Regulatory Framework
- 6.4.8.4. Reimbursement scenario
- 6.4.8.5. Norway Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.9. Sweden
- 6.4.9.1. Key Country Dynamics
- 6.4.9.2. Competitive Scenario
- 6.4.9.3. Regulatory Framework
- 6.4.9.4. Reimbursement scenario
- 6.4.9.5. Sweden Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Asia Pacific Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. China
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Competitive Scenario
- 6.5.2.3. Regulatory Framework
- 6.5.2.4. Reimbursement scenario
- 6.5.2.5. China Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Japan
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Competitive Scenario
- 6.5.3.3. Regulatory Framework
- 6.5.3.4. Reimbursement scenario
- 6.5.3.5. Japan Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.4. India
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Competitive Scenario
- 6.5.4.3. Regulatory Framework
- 6.5.4.4. Reimbursement scenario
- 6.5.4.5. India Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.5. South Korea
- 6.5.5.1. Key Country Dynamics
- 6.5.5.2. Competitive Scenario
- 6.5.5.3. Regulatory Framework
- 6.5.5.4. Reimbursement scenario
- 6.5.5.5. South Korea Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.6. Australia
- 6.5.6.1. Key Country Dynamics
- 6.5.6.2. Competitive Scenario
- 6.5.6.3. Regulatory Framework
- 6.5.6.4. Reimbursement scenario
- 6.5.6.5. Australia Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.7. Thailand
- 6.5.7.1. Key Country Dynamics
- 6.5.7.2. Competitive Scenario
- 6.5.7.3. Regulatory Framework
- 6.5.7.4. Reimbursement scenario
- 6.5.7.5. Thailand Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Latin America Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Brazil
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Competitive Scenario
- 6.6.2.3. Regulatory Framework
- 6.6.2.4. Reimbursement scenario
- 6.6.2.5. Brazil Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Mexico
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Competitive Scenario
- 6.6.3.3. Regulatory Framework
- 6.6.3.4. Reimbursement scenario
- 6.6.3.5. Mexico Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.4. Argentina
- 6.6.4.1. Key Country Dynamics
- 6.6.4.2. Competitive Scenario
- 6.6.4.3. Regulatory Framework
- 6.6.4.4. Reimbursement scenario
- 6.6.4.5. Argentina Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. Middle East & Africa
- 6.7.1. Middle East & Africa Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Competitive Scenario
- 6.7.2.3. Regulatory Framework
- 6.7.2.4. Reimbursement scenario
- 6.7.2.5. South Africa Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.3. Saudi Arabia
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Competitive Scenario
- 6.7.3.3. Regulatory Framework
- 6.7.3.4. Reimbursement scenario
- 6.7.3.5. Saudi Arabia Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.4. UAE
- 6.7.4.1. Key Country Dynamics
- 6.7.4.2. Competitive Scenario
- 6.7.4.3. Regulatory Framework
- 6.7.4.4. Reimbursement scenario
- 6.7.4.5. UAE Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.5. Kuwait
- 6.7.5.1. Key Country Dynamics
- 6.7.5.2. Competitive Scenario
- 6.7.5.3. Regulatory Framework
- 6.7.5.4. Reimbursement scenario
- 6.7.5.6. Kuwait Leadless Pacemakers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Company/Competition Categorization
- 7.2. Company Profiles
- 7.2.1. Abbott
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Medtronic
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. EBR Systems Inc.
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Boston Scientific Corporation
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. MicroPort Scientific Corporation
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives